Skip to main content

Dermata Therapeutics, Inc.

corporate_fare Company Profile

Dermata Therapeutics, Inc.

DRMA·NASDAQ·Life Sciences·CIK 0001853816

Dermata Therapeutics, Inc. is a scientific leader in skincare, dedicated to the development and commercialization of products addressing common and underserved skin conditions. The Company was initially founded to research and develop prescription products. Its lead asset, XYNGARI (also known as DMT310), was studied in clinical trials for moderate-to-severe acne. In March 2025, Dermata announced statistically significant results from its Phase 3 STAR-1 clinical trial of XYNGARI, which demonstrated statistically significant results across all three co-primary endpoints at weeks 4, 8, and 12 when compared with placebo. Following this trial, in September 2025, management, with board support, shifted strategy to developing and distributing direct-to-consumer (DTC) and business-to-business (B2B) skincare products. This strategic repositioning aims to accelerate commercialization, reduce regulatory burden, and decrease development expenses by leveraging the Company's dermatology knowledge to create effective and safe skincare products available without a prescription.

Dermata Therapeutics, Inc. (NASDAQ:DRMA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for DRMA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for DRMA spans 10-Q, 8-K, SCHEDULE 13D, 424B3.

Recent high-impact activity:

  • Dermata Q3: First Tome Revenue of $74K, $4.8M Cash, Going Concern Reaffirmed
  • Dermata Posts First $74K in Product Sales, But Cash Runs Dry by Q1 2027
  • Dermata Secures $3.4M Private Placement with Insider Backing
  • Dermata Q2 Cash Drops to $4.4M, Runway Only Into Q4; Going Concern Warning Reiterated
  • Dermata Posts Q2 Loss, Targets August 25 Debut for First Skincare Line

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$7.56M
Diluted EPS
-$8.16
Op. Cash Flow
-$7.76M
Operating Income
-$7.77M
Cash & Equivalents
$7.52M
Debt / Equity
0.00×
Shares Outstanding
2.66M sh
Source: 10-K · filed 2026-03-26 · accession 0001493152-26-012992

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 84,233 shares in DRMA as of the October 30, 2026 settlement, a 9.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 45.8% of DRMA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)84,233 shares as of October 30, 2026
Change vs prior period▲ 9.0%
Days to cover1.00 at avg daily volume of 406,501
Daily short volume (FINRA facilities)45.8% of 12,021 shares on November 20, 2026
5-day average short volume38.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for DRMA, detected from its recent SEC filings · based on capital-structure filings through 2026-05-29.

1 recent capital raiseATM program1 shelf registration

Universal Shelf Offering Finalized · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$0.51 +0.10% today
52-week range · as of 2026-11-10 $0.51 – $4.66
Market cap
$2.51M
Volume
26.7K (0.0× avg)
3-mo avg 5.9M
Live data · 2026-11-22 03:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DRMA - Latest Insights

DRMA
Nov 10, 2026, 4:07 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.702
Real-time Price: $0.510 info
Change: -$0.192 (-27%) info
Market Cap: $2.512M info
DRMA
Nov 10, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $0.510 info
Change: -$0.210 (-29%) info
Market Cap: $2.512M info
DRMA
Aug 17, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.43
Real-time Price: $0.510 info
Change: -$0.920 (-64%) info
Market Cap: $2.512M info
DRMA
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.71
Real-time Price: $0.510 info
Change: -$1.20 (-70%) info
Market Cap: $2.512M info
DRMA
Aug 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.10
Real-time Price: $0.510 info
Change: -$0.590 (-54%) info
Market Cap: $2.512M info
DRMA
Aug 05, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.510 info
Change: -$0.630 (-55%) info
Market Cap: $2.512M info
DRMA
Jun 01, 2026, 4:34 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $1.36
Real-time Price: $0.510 info
Change: -$0.854 (-63%) info
Market Cap: $2.512M info
DRMA
May 29, 2026, 5:25 PM EDT
Filing Type: 424B3
Importance Score:
8
Price at Filing: $1.29
Real-time Price: $0.510 info
Change: -$0.780 (-60%) info
Market Cap: $2.512M info
DRMA
May 27, 2026, 4:57 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $0.510 info
Change: -$0.790 (-61%) info
Market Cap: $2.512M info
DRMA
May 22, 2026, 5:15 PM EDT
Filing Type: S-3/A
Importance Score:
9
Price at Filing: $1.26
Real-time Price: $0.510 info
Change: -$0.750 (-60%) info
Market Cap: $2.512M info
DRMA
May 13, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.16
Real-time Price: $0.510 info
Change: -$0.650 (-56%) info
Market Cap: $2.512M info
DRMA
May 13, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.16
Real-time Price: $0.510 info
Change: -$0.650 (-56%) info
Market Cap: $2.512M info
DRMA
May 13, 2026, 4:05 PM EDT
Source: Access Newswire
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $0.510 info
Change: -$0.700 (-58%) info
Market Cap: $2.512M info
DRMA
Apr 17, 2026, 5:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.38
Real-time Price: $0.510 info
Change: -$0.870 (-63%) info
Market Cap: $2.512M info
DRMA
Apr 17, 2026, 5:01 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $1.38
Real-time Price: $0.510 info
Change: -$0.870 (-63%) info
Market Cap: $2.512M info
DRMA
Apr 02, 2026, 8:30 AM EDT
Source: Access Newswire
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.510 info
Change: -$0.690 (-58%) info
Market Cap: $2.512M info
DRMA
Mar 26, 2026, 5:25 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.38
Real-time Price: $0.510 info
Change: -$0.8693 (-63%) info
Market Cap: $2.512M info
DRMA
Mar 26, 2026, 5:17 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.36
Real-time Price: $0.510 info
Change: -$0.850 (-63%) info
Market Cap: $2.512M info
DRMA
Mar 26, 2026, 5:15 PM EDT
Source: Access Newswire
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $0.510 info
Change: -$0.840 (-62%) info
Market Cap: $2.512M info
DRMA
Feb 25, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.22
Real-time Price: $0.510 info
Change: -$0.710 (-58%) info
Market Cap: $2.512M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets